WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406223

CAS#: 137530-61-1

Description: BE-16627B is a novel metalloproteinase (MP) inhibitor isolated from Streptomyces sp. BE16627B selectively inhibited MPs such as human stromelysin and 92 kD gelatinase. After the cells were cultured with BE16627B for 5 days, BE16627B inhibited MP activity in the primary culture supernatants from synovial cells in a dose-dependent fashion without showing apparent cytotoxicity or affecting the production and secretion of MPs. Its IC50 for active collagenolysis before activation by trypsin was 25 microM.

Price and Availability




BE-16627B, purity > 98%, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 406223
Name: BE-16627B
CAS#: 137530-61-1
Chemical Formula: C16H29N3O7
Exact Mass: 375.20055
Molecular Weight: 375.42
Elemental Analysis: C, 51.19; H, 7.79; N, 11.19; O, 29.83

Synonym: BE16627B; BE 16627B; BE-16627B; LN(Nhydroxy2isobutylsuccinamoyl)serylLvaline.

IUPAC/Chemical Name: (2S)-2-((2S)-3-hydroxy-2-(2-(2-(hydroxyamino)-2-oxoethyl)-4-methylpentanamido)propanamido)-3-methylbutanoic acid

SMILES Code: CC(C)[C@H](NC([C@@H](NC(C(CC(NO)=O)CC(C)C)=O)CO)=O)C(O)=O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

Additional Information



1: Yoshida D, Watanabe K, Takahashi H, Sugisaki Y, Teramoto A. Apoptotic induction by BE16627B on human malignant glioma cell lines by an anti-matrix metalloproteinase agent. Brain Tumor Pathol. 2003;20(1):13-9. PubMed PMID: 14604227.

2: Sobue T, Hakeda Y, Kobayashi Y, Hayakawa H, Yamashita K, Aoki T, Kumegawa M, Noguchi T, Hayakawa T. Tissue inhibitor of metalloproteinases 1 and 2 directly stimulate the bone-resorbing activity of isolated mature osteoclasts. J Bone Miner Res. 2001 Dec;16(12):2205-14. PubMed PMID: 11760833.

3: Watanabe K, Yoshida D, Noha M, Teramoto A. Suppression of matrix metalloproteinase-2 and -9 mediated invasiveness by a novel matrix metalloproteinase inhibitor, BE16627B. J Neurooncol. 2001 Mar;52(1):1-9. PubMed PMID: 11451198.

4: Kiyama T, Onda M, Tokunaga A, Efron DT, Barbul A. Effect of matrix metalloproteinase inhibition on colonic anastomotic healing in rats. J Gastrointest Surg. 2001 May-Jun;5(3):303-11. PubMed PMID: 11360054.

5: Shibutani T, Yamashita K, Aoki T, Iwayama Y, Nishikawa T, Hayakawa T. Tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) stimulate osteoclastic bone resorption. J Bone Miner Metab. 1999;17(4):245-51. PubMed PMID: 10575588.

6: Okuyama A, Akiyama T, Nakajima M. [CDK and MMP inhibitors]. Gan To Kagaku Ryoho. 1997 Sep;24(11):1547-62. Review. Japanese. PubMed PMID: 9309154.

7: Tamaki K, Tanzawa K, Kurihara S, Oikawa T, Monma S, Shimada K, Sugimura Y. Synthesis and structure-activity relationships of gelatinase inhibitors derived from matlystatins. Chem Pharm Bull (Tokyo). 1995 Nov;43(11):1883-93. PubMed PMID: 8575029.

8: Okuyama A, Naito K, Morishima H, Suda H, Nishimura S, Tanaka N. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Ann N Y Acad Sci. 1994 Sep 6;732:408-10. PubMed PMID: 7978821.

9: Naito K, Kanbayashi N, Nakajima S, Murai T, Arakawa K, Nishimura S, Okuyama A. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int J Cancer. 1994 Sep 1;58(5):730-5. PubMed PMID: 8077060.

10: Naito K, Nakajima S, Kanbayashi N, Okuyama A, Goto M. Inhibition of metalloproteinase activity of rheumatoid arthritis synovial cells by a new inhibitor [BE16627B; L-N-(N-hydroxy-2-isobutylsuccinamoyl)-seryl-L-valine]. Agents Actions. 1993 Jul;39(3-4):182-6. PubMed PMID: 8304246.